China Resources Double-Crane Pharmaceutical Co.,Ltd.

Symbol: 600062.SS

SHH

23.35

CNY

Market price today

  • 17.5971

    P/E Ratio

  • -0.5329

    PEG Ratio

  • 24.20B

    MRK Cap

  • 0.01%

    DIV Yield

China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062-SS) Stock Price & Analysis

Shares Outstanding

1036.3M

Gross Profit Margin

0.55%

Operating Profit Margin

0.15%

Net Profit Margin

0.13%

Return on Assets

0.09%

Return on Equity

0.13%

Return on Capital Employed

0.12%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Wenchao Lu
Full-time employees:12269
City:Beijing
Address:No. 1, Lize East 2nd Road
IPO:1997-05-22
CIK:

China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its subsidiaries, operates as a pharmaceutical company in the People's Republic of China. The company offers soft bag, plastic and glass bottle, inner sealed polypropylene, and polypropylene blend bag infusion products; levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, sodium chloride injection products, etc.; and peritoneal dialysate, hemodialysis dialysate, etc. It also provides compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, edaravone, and other products to treat cardiovascular and cerebrovascular diseases. In addition, the company offers products for endocrinology; and pediatric compound amino acid injection, and other drugs to treat pediatrics. Further, it provides nutritional drugs, including vitamin E and C; and anti-infective drugs. The company is headquartered in Beijing, the People's Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. is a subsidiary of Beijing Pharmaceutical Group Co., Ltd.

General Outlook

In simple terms, China Resources Double-Crane Pharmaceutical Co.,Ltd. has 1036.301 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.554% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.147%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.134%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.088% return, is a testament to China Resources Double-Crane Pharmaceutical Co.,Ltd.'s adeptness in optimizing resource deployment. China Resources Double-Crane Pharmaceutical Co.,Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.125%. Furthermore, the proficiency of China Resources Double-Crane Pharmaceutical Co.,Ltd. in capital utilization is underscored by a remarkable 0.119% return on capital employed.

Stock Prices

China Resources Double-Crane Pharmaceutical Co.,Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $20.87, while its low point bottomed out at $20.36. This variance in figures offers investors a lucid insight into the roller-coaster ride that is China Resources Double-Crane Pharmaceutical Co.,Ltd.'s stock market.

Liquidity Ratios

Analyzing 600062.SS liquidity ratios reveals its financial health of the firm. The current ratio of 260.80% gauges short-term asset coverage for liabilities. The quick ratio (207.87%) assesses immediate liquidity, while the cash ratio (120.95%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio260.80%
Quick Ratio207.87%
Cash Ratio120.95%

Profitability Ratios

600062.SS profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 15.60% underscores its earnings before tax deductions. The effective tax rate stands at 16.66%, revealing its tax efficiency. The net income per EBT, 85.80%, and the EBT per EBIT, 106.10%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 14.70%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin15.60%
Effective Tax Rate16.66%
Net Income per EBT85.80%
EBT per EBIT106.10%
EBIT per Revenue14.70%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.61, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 392.24% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding208
Days of Inventory Outstanding109
Operating Cycle202.28
Days of Payables Outstanding51
Cash Conversion Cycle152
Receivables Turnover3.92
Payables Turnover7.20
Inventory Turnover3.34
Fixed Asset Turnover2.68
Asset Turnover0.66

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 1.75, and free cash flow per share, 1.16, depict cash generation on a per-share basis. The cash per share value, 3.51, showcases liquidity position. A payout ratio of 0.22 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.18, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share1.75
Free Cash Flow per Share1.16
Cash per Share3.51
Payout Ratio0.22
Operating Cash Flow Sales Ratio0.18
Free Cash Flow to Operating Cash Flow Ratio0.66
Cash Flow Coverage Ratio5.84
Short Term Coverage Ratio6.50
Capital Expenditure Coverage Ratio2.97
Dividend Paid and Capex Coverage Ratio1.98
Dividend Payout Ratio0.02

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 1.98%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.03, we discern the balance between debt and equity financing. The long-term debt to capitalization, 0.27%, and total debt to capitalization, 2.63%, ratios shed light on its capital structure. An interest coverage of 110.11 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio1.98%
Debt Equity Ratio0.03
Long Term Debt to Capitalization0.27%
Total Debt to Capitalization2.63%
Interest Coverage110.11
Cash Flow to Debt Ratio5.84
Company Equity Multiplier1.36

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 9.84, provides a glimpse into top-line earnings distributed across each share. Net income per share, 1.30, reflects the portion of profit attributed to each share. The book value per share, 10.82, represents the net asset value distributed per share, while the tangible book value per share, 8.37, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share9.84
Net Income Per Share1.30
Book Value Per Share10.82
Tangible Book Value Per Share8.37
Shareholders Equity Per Share10.82
Interest Debt Per Share0.47
Capex Per Share-0.59

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 6.80%, indicates top-line expansion, while the gross profit growth, -1.42%, reveals profitability trends. EBIT growth, 3.60%, and operating income growth, 3.60%, offer insights into operational profitability progression. The net income growth, 12.96%, showcases bottom-line expansion, and the EPS growth, 14.04%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth6.80%
Gross Profit Growth-1.42%
EBIT Growth3.60%
Operating Income Growth3.60%
Net Income Growth12.96%
EPS Growth14.04%
EPS Diluted Growth14.04%
Weighted Average Shares Growth-0.99%
Weighted Average Shares Diluted Growth-0.99%
Dividends per Share Growth-61.47%
Operating Cash Flow Growth23.04%
Free Cash Flow Growth28.20%
10-Year Revenue Growth per Share18.54%
5-Year Revenue Growth per Share24.82%
3-Year Revenue Growth per Share20.72%
10-Year Operating CF Growth per Share142.66%
5-Year Operating CF Growth per Share14.34%
3-Year Operating CF Growth per Share23.50%
10-Year Net Income Growth per Share22.93%
5-Year Net Income Growth per Share40.04%
3-Year Net Income Growth per Share34.95%
10-Year Shareholders Equity Growth per Share66.99%
5-Year Shareholders Equity Growth per Share43.94%
3-Year Shareholders Equity Growth per Share21.42%
10-Year Dividend per Share Growth per Share13.07%
5-Year Dividend per Share Growth per Share241.61%
3-Year Dividend per Share Growth per Share-2.53%
Receivables Growth1.72%
Inventory Growth-16.83%
Asset Growth7.00%
Book Value per Share Growth11.76%
Debt Growth74.68%
R&D Expense Growth-10.78%
SGA Expenses Growth16.48%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 16,705,834,452.9, captures the company's total value, considering both debt and equity. Income quality, 1.24, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.02, gauges operational efficiency, while the research and development to revenue, 4.20%, highlights investment in innovation. The ratio of intangibles to total assets, 21.87%, indicates the value of non-physical assets, and capex to operating cash flow, -36.62%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value16,705,834,452.9
Income Quality1.24
Sales General and Administrative to Revenue0.02
Research and Development to Revenue4.20%
Intangibles to Total Assets21.87%
Capex to Operating Cash Flow-36.62%
Capex to Revenue-5.99%
Capex to Depreciation-92.22%
Stock-Based Compensation to Revenue0.50%
Graham Number17.79
Return on Tangible Assets11.01%
Graham Net Net2.45
Working Capital4,476,373,422
Tangible Asset Value8,582,080,590
Net Current Asset Value4,112,402,276
Average Receivables2,383,133,459
Average Payables720,605,753
Average Inventory1,720,536,466
Days Sales Outstanding87
Days Payables Outstanding51
Days of Inventory On Hand115
ROIC10.66%
ROE0.12%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.10, and the price to book ratio, 2.10, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.35, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 20.02, and price to operating cash flows, 13.33, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio2.10
Price to Book Ratio2.10
Price to Sales Ratio2.35
Price Cash Flow Ratio13.33
Price Earnings to Growth Ratio-0.53
Enterprise Value Multiple15.91
Price Fair Value2.10
Price to Operating Cash Flow Ratio13.33
Price to Free Cash Flows Ratio20.02
Price to Tangible Book Ratio1.75
Enterprise Value to Sales1.66
Enterprise Value Over EBITDA7.91
EV to Operating Cash Flow10.12
Earnings Yield6.85%
Free Cash Flow Yield5.38%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS) on the SHH in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 17.597 in 2024.

What is the ticker symbol of China Resources Double-Crane Pharmaceutical Co.,Ltd. stock?

The ticker symbol of China Resources Double-Crane Pharmaceutical Co.,Ltd. stock is 600062.SS.

What is company IPO date?

IPO date of China Resources Double-Crane Pharmaceutical Co.,Ltd. is 1997-05-22.

What is company current share price?

Current share price is 23.350 CNY.

What is stock market cap today?

The market cap of stock today is 24197621112.000.

What is PEG ratio in 2024?

The current -0.533 is -0.533 in 2024.

What is the number of employees in 2024?

In 2024 the company has 12269.